Lung Cancer Clinical Trial
Official title:
Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting as a Potential Teachable Moment for Actively Smoking Family Members
Verified date | January 2024 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this pilot study is to examine, in an innovative setting, the potential for a lung cancer diagnosis in a loved one to represent a teachable moment for smoking cessation in family members or caregivers who are current smokers. The researchers will identify the willingness and preferred modality for smoking cessation among family members/caregivers in this setting. The researchers will estimate abstinence rates at 4, 8, 12, and 24 weeks..
Status | Terminated |
Enrollment | 4 |
Est. completion date | March 29, 2022 |
Est. primary completion date | March 29, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Patient Inclusion Criteria: 1. patient with newly diagnosed lung cancer within the last 6 months of initial diagnosis/confirmation of diagnosis at the study sites 2. Able to provide informed consent 3. Able to speak and read English Family Member/Caregiver Participant Criteria: 1. Family member or caregiver (defined as first degree relative [parent, sibling, child] or person living in the same household) 2. Family member or caregiver must be a current, active smoker (defined as 10 cigarettes per day for 6 consecutive months). 3. At least 18 years of age at time of study consent 4. Able to provide informed consent 5. Able to speak and read English Exclusion Criteria: 1. Currently receiving formal tobacco dependence treatment- Nicotine replacement of any kind, varenicycline or Bupropion. 2. Medical condition that precludes proposed pharmacotherapy for smoking cessation : Recent (= 2 weeks) myocardial infarction , history of underlying arrhythmias , history of serious or worsening angina pectoris, pregnancy and breastfeeding |
Country | Name | City | State |
---|---|---|---|
United States | Indiana University Melvin & Bren Simon Cancer Center | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 7-day point prevalence of self -reported smoking cessation | 4 weeks | ||
Primary | 7-day point prevalence of self -reported smoking cessation | 8 weeks | ||
Primary | 7-day point prevalence of self -reported smoking cessation | 12 weeks | ||
Primary | 7-day point prevalence of self -reported smoking cessation | 24 weeks | ||
Primary | Willingness to quit | 4 weeks | ||
Primary | Willingness to quit | 8 weeks | ||
Primary | Willingness to quit | 12 weeks | ||
Primary | Willingness to quit | 24 weeks | ||
Primary | Preference for type of cessation intervention modality | digital versus traditional support with nicotine replacement therapy [NRT] | 4 weeks | |
Primary | Preference for type of cessation intervention modality | digital versus traditional support with nicotine replacement therapy [NRT] | 8 weeks | |
Primary | Preference for type of cessation intervention modality | digital versus traditional support with nicotine replacement therapy [NRT] | 12 weeks | |
Primary | Preference for type of cessation intervention modality | digital versus traditional support with nicotine replacement therapy [NRT] | 24 weeks | |
Secondary | Mean change in readiness to quit | Measured via the Readiness to Quit Ladder | Baseline | |
Secondary | Mean change in readiness to quit | Measured via the Readiness to Quit Ladder | 4 weeks | |
Secondary | Mean change in readiness to quit | Measured via the Readiness to Quit Ladder | 8 weeks | |
Secondary | Mean change in readiness to quit | Measured via the Readiness to Quit Ladder | 12 weeks | |
Secondary | Mean change in readiness to quit | Measured via the Readiness to Quit Ladder | 24 weeks | |
Secondary | Mean change in nicotine dependence | Measured via the Heaviness of Smoking Index | Baseline | |
Secondary | Mean change in nicotine dependence | Measured via the Heaviness of Smoking Index | 4 weeks | |
Secondary | Mean change in nicotine dependence | Measured via the Heaviness of Smoking Index | 8 weeks | |
Secondary | Mean change in nicotine dependence | Measured via the Heaviness of Smoking Index | 12 weeks | |
Secondary | Mean change in nicotine dependence | Measured via the Heaviness of Smoking Index | 24 weeks | |
Secondary | Mean change in cigarette use | Measured by by the self-reported number of cigarettes smoked per day | Baseline | |
Secondary | Mean change in cigarette use | Measured by by the self-reported number of cigarettes smoked per day | 4 weeks | |
Secondary | Mean change in cigarette use | Measured by by the self-reported number of cigarettes smoked per day | 8 weeks | |
Secondary | Mean change in cigarette use | Measured by by the self-reported number of cigarettes smoked per day | 12 weeks | |
Secondary | Mean change in cigarette use | Measured by by the self-reported number of cigarettes smoked per day | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|